Gain Therapeutics

Novel Parkinson's Treatment Begins Clinical Trials

About this Event

Watch our Fireside Chat with:
Matthias Adler: CEO of Gain Therapeutics
John Vandermosten: CFA, Senior Analyst for Zacks Small-Cap Research

This discussion covered how Gain Therapeutics (NASDAQ: GANX) is transforming drug discovery with its AI and supercomputer-powered technology platform SEE-Tx, accelerating the drug discovery process from more than 2 years to less than 3 months.

Gain has unlocked new treatment approaches by enabling the identification of novel protein binding sites, and is currently developing GT-02287 a new drug for the treatment of Parkinson’s disease.

This novel approach also has therapeutic potential in multiple additional neurodegenerative diseases, including Gaucher disease, idiopathic Parkinson’s disease, Lewy body dementia, and Alzheimer’s, creating a total addressable market that exceeds $15B.

Video On Demand

– Recorded

December 5

SHARE THIS EVENT

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.